Aspen Neuroscience’s autologous, personalised stem cell therapy is set for a pivotal trial after it showed improved "ON" and ...
March 20 (Reuters) - The U.S. Food and Drug Administration said on Friday it has notified manufacturers of certain ...
Fatigue, cognitive changes and sleep disturbances were as important to patients with early Parkinson’s disease as symptoms ...
Aspen Neuroscience’s stem cell therapy improved Parkinson’s disease symptoms for all eight treated patients after one year, with the San Diego biotech now planning for a pivotal phase 3 trial later ...
A Finnish clinical imaging study shows that rest tremor in Parkinson's disease is not explained by greater dopamine loss. In ...
Timely diagnosis of debilitating and often deadly brain diseases such as Alzheimer’s and Parkinson’s remains largely elusive, though in recent years several teams of scientists have reported potential ...
Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such ...
GlobalData on MSN
Parkinson’s research reaches “pivotal” stage, but barriers remain
Funding and clinical trial-based barriers must be addressed to ensure success on the path to developing a DMT for Parkinson’s.
ARV-102 reduced endolysosomal and neuroinflammatory biomarkers implicated in Parkinson’s disease and progressive supranuclear ...
Scientists at the University of Edinburgh in Scotland used biologically-engineered E. coli, a bacteria that causes diarrhea, ...
From standard medications to advanced drug delivery, surgery, and regenerative approaches, Parkinson's treatment options in ...
Japan has approved two stem cell-based therapies for treating Parkinson's disease and heart failure in a world first, through ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results